Developer docs
API playgroundTry for free, no card

Search company profiles

Celeris Therapeutics

Full company profile

uuid00021xe

Namestring
Celeris Therapeutics
Legal namestring
Vavada
Websiteurl
celeristx.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Celeris Therapeutics is a Menlo Park, California-based drug discovery company founded in 2021 that applies deep learning combined with laboratory automation to develop therapeutics in the targeted protein degradation (TPD) modality. The company's platform is designed to accelerate the identification and optimization of degrader molecules — a therapeutic class that works by hijacking the cell's own protein disposal machinery to eliminate disease-causing proteins — by integrating computational prediction with automated wet-lab experimentation. This closed-loop approach is intended to compress design-make-test-analyze cycles relative to traditional medicinal chemistry workflows.

The company is privately held and small, with a reported headcount of 11-50 employees, and operates as a for-profit entity. Celeris has not disclosed a public-facing product catalog, named pipeline assets, or commercial partnerships in the available data; its current outputs are research-stage rather than revenue-generating. The company's go-to-market posture is consistent with a pre-clinical platform play, where long-term value creation depends on either internal pipeline advancement to IND-enabling stages, out-licensing of degrader programs, or strategic partnerships with larger pharmaceutical companies.

Between March 2021 and October 2022, Celeris raised approximately $17 million across five funding rounds from a mix of European and U.S. investors, led most recently by the European Innovation Council in two tranches. Earlier rounds brought in APEX Ventures, i&i Prague, Longevitytech.fund, Pace Ventures, and R42 Group. The investor mix — spanning biotech specialists, deep-tech funds, and longevity-focused capital — reflects the cross-disciplinary nature of the company's AI-biology platform. No disclosures of revenue, licensing income, or commercial customers were available in the input, consistent with a pre-revenue, research-stage operating model.

Short descriptiontext

Celeris Therapeutics is a Menlo Park-based drug discovery company founded in 2021 that combines deep learning with lab automation to develop targeted protein degradation therapeutics. It serves the pre-clinical biopharmaceutical pipeline as a research-stage platform with no disclosed commercial customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMenlo Park, United States
HQ citystring
Menlo Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
targeted protein degradation, drug discovery, deep learning biotechnology, lab automation, PROTAC therapeutics
Industry3 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
Product category
Biotechnology Drug Discovery
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Casino House Edge
TypeTransaction Fee
Description

Revenue generated from the mathematical house edge across slot machines, table games, and live dealer games. Average slot RTP stated at 95.5%, meaning the casino retains approximately 4.5% of wagers over time.

mingahoitzam.org
2VIP Program and Loyalty
TypeSubscription Recurring
Description

Tiered VIP program with escalating perks including higher cashout limits, access to private tournaments, personal account managers, and exclusive bonus offers.

mingahoitzam.org
3Tournament Entry Fees
TypeTransaction Fee
Description

Formal tournaments where players compete for prize pools funded partly by entry mechanics; prizes range from $100 to $12,000.

mingahoitzam.org
4Bonus Wagering Requirements
TypeTransaction Fee
Description

Wagering requirements (x20-x35 multipliers) on bonus funds before withdrawal creates revenue from unfulfilled playthroughs.

mingahoitzam.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Welcome Bonus - 100 Free Spins on Great Pigsby Megaways
ModelFreemiumBilling cadencePay-as-you-go
Notes

100 free spins for new account registration; winnings subject to x20 wagering requirement within 14 days

mingahoitzam.org
2First Deposit Match Bonus up to $1,000
ModelFreemiumBilling cadencePay-as-you-go
Notes

100% match on first deposit up to $1,000 maximum; subject to x35 wagering requirement within 2 weeks

mingahoitzam.org
3Cashback - 10% Monthly
ModelUsage-basedBilling cadenceMonthly
Notes

10% compensation on net losses (losses exceed winnings); subject to x5 wagering; only for players who lost more than won

mingahoitzam.org
4VIP Tier Benefits
ModelSubscriptionBilling cadenceAnnual
Notes

VIP status unlocks: higher cashout limits, access to private tournaments with $7,500 prizes, personal account managers, free spin giveaways

mingahoitzam.org
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Celeris Therapeutics is a drug discovery company that uses deep learning combined with lab automation to accelerate the identification and optimization of targeted protein degradation therapeutics. Its work centers on designing degrader molecules (such as PROTACs) that can be developed into clinical assets for pharmaceutical partners or internal programs. The company operates as a discovery-stage biotech, leveraging AI-driven target identification and automated wet-lab workflows to compress traditional medicinal chemistry timelines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Average 95.5% RTP across slots and table games, meaning 95% of bets return with multipliers from x1.1 to x100,000
+3 more records
Product overview1 text field

Vavada Online Casino is a single unified online gambling platform offering over 5000 games including slots, table games, live dealer games, crash games, and sports betting. The platform is accessible via desktop web browser, mobile browser, and dedicated iOS and Android applications. The ecosystem includes tournament systems, a VIP program with personalized account managers, and a bonus system with welcome bonuses, cashback, and promotional codes.

Product and service1 record
1Targeted Protein Degradation Discovery Platform
CategoryDrug Discovery Services
Description

Drug discovery service that combines AI-driven target prediction with automated wet-lab experimentation to identify and optimize targeted protein degrader candidates for pharmaceutical and biotechnology partners.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Curaçao Gaming Control Board
Strategic tierCoreTypeOthersAnnounced on2017-01-01
Description

Regulatory licensing authority providing international gaming license for legal operation. The regulator monitors random algorithm functioning, payout fund availability, and security against hacking to protect player rights.

mingahoitzam.org
241 Gaming Providers (NetEnt, Pragmatic Play, Play'n Go, Yggdrasil, PG Soft, Red Tiger, Quickspin, iSoftBet, Hacksaw Gaming, and others)
Strategic tierCoreTypeTechnology or Integration
Description

Content partnership providing over 5,000 casino game titles across slots, table games, live dealer, and crash game categories. Providers include 1x2 Gaming, Amatic, Belatra Games, BGaming, Blueprint Gaming, EGT Digital, ELK, Endorphina, Habanero, Igrosoft, NetEnt, Nolimit City, Playson, Playtech, Push Gaming, Thunderkick, Yggdrasil, and others.

mingahoitzam.org
3Content Creator/Streamer Partners
Strategic tierMinorTypeGTM or Marketing Partner
Description

Affiliate partners who stream casino gameplay on YouTube, provide reviews and tutorials, and distribute promotional codes to their audiences. Contact support for full partner list.

mingahoitzam.org
420 Financial Services (Payment Processors)
Strategic tierCoreTypeTechnology or Integration
Description

Payment processing partnerships enabling deposits and withdrawals across 20 currencies including cryptocurrency. Services ensure seamless financial operations without commissions.

mingahoitzam.org
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer and leader in clinical-stage PROTAC-based protein degradation. Most directly comparable to Celeris on the TPD modality, though at much later stage with partnered assets (Pfizer, Bayer) and FDA-submitted programs.

TypeDirect peer
Description

Clinical-stage TPD company with multiple degrader programs and major pharma partnerships (Sanofi, Vertex). Directly competes with Celeris for talent, targets, and pharma BD opportunities in protein degradation.

TypeDirect peer
Description

Clinical-stage TPD company developing small-molecule degraders (e.g., CFT7455 for multiple myeloma). Direct peer in the protein degradation space with comparable scientific focus on targeted protein destruction.

TypeDirect peer
Description

Discovery-stage TPD and chromatin-targeted company. Similar early-stage profile to Celeris and competing in the same protein-degradation talent and partnership ecosystem.

TypeDirect peer
Description

AI-native drug discovery company combining generative deep learning with automated wet-lab biology. Closest comparable on the AI/ML + lab automation thesis underlying Celeris's platform.

TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput automated biology with ML. Comparable technology stack and modality-agnostic approach to Celeris's AI + lab automation model.

TypeDirect peer
Description

Computational drug discovery platform combining physics-based modeling with ML. Comparable in offering ML-driven discovery tools to pharma, though more mature, publicly traded, and software-licensing-heavy in business model.

TypeDirect peer
Description

AI-driven generative biology platform designing protein therapeutics. Overlapping AI + lab automation thesis with Celeris, though focused on biologics generation rather than small-molecule TPD.

9Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company with substantially more capital, compute, and AlphaFold-derived IP. A broader incumbent in AI-native drug discovery and a credible long-term competitor for pharma BD deals.

TypeBroad incumbent
Description

Large biopharma with internal TPD investment and partnerships (e.g., with Arvinas and Kymera). Represents both a structural competitive threat to TPD-discovery startups and a potential partner/acquirer for Celeris's platform.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celeris Therapeutics

Biotechnology Drug Discoveryceleristx.com

Celeris Therapeutics is a Menlo Park-based drug discovery company founded in 2021 that combines deep learning with lab automation to develop targeted protein degradation therapeutics. It serves the pre-clinical biopharmaceutical pipeline as a research-stage platform with no disclosed commercial customers.

What Celeris Therapeutics does

Celeris Therapeutics is a Menlo Park, California-based drug discovery company founded in 2021 that applies deep learning combined with laboratory automation to develop therapeutics in the targeted protein degradation (TPD) modality. The company's platform is designed to accelerate the identification and optimization of degrader molecules — a therapeutic class that works by hijacking the cell's own protein disposal machinery to eliminate disease-causing proteins — by integrating computational prediction with automated wet-lab experimentation. This closed-loop approach is intended to compress design-make-test-analyze cycles relative to traditional medicinal chemistry workflows.

The company is privately held and small, with a reported headcount of 11-50 employees, and operates as a for-profit entity. Celeris has not disclosed a public-facing product catalog, named pipeline assets, or commercial partnerships in the available data; its current outputs are research-stage rather than revenue-generating. The company's go-to-market posture is consistent with a pre-clinical platform play, where long-term value creation depends on either internal pipeline advancement to IND-enabling stages, out-licensing of degrader programs, or strategic partnerships with larger pharmaceutical companies.

Between March 2021 and October 2022, Celeris raised approximately $17 million across five funding rounds from a mix of European and U.S. investors, led most recently by the European Innovation Council in two tranches. Earlier rounds brought in APEX Ventures, i&i Prague, Longevitytech.fund, Pace Ventures, and R42 Group. The investor mix — spanning biotech specialists, deep-tech funds, and longevity-focused capital — reflects the cross-disciplinary nature of the company's AI-biology platform. No disclosures of revenue, licensing income, or commercial customers were available in the input, consistent with a pre-revenue, research-stage operating model.

Celeris Therapeutics firmographics

Firmographics
Name
Celeris Therapeutics
Legal name
Vavada
Website
https://celeristx.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Celeris Therapeutics is a Menlo Park-based drug discovery company founded in 2021 that combines deep learning with lab automation to develop targeted protein degradation therapeutics. It serves the pre-clinical biopharmaceutical pipeline as a research-stage platform with no disclosed commercial customers.
Ownership category
akta.pro rank

Celeris Therapeutics industry classification

Industry
Product category
Biotechnology Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Targeted protein degradation
  • Drug discovery
  • Deep learning biotechnology
  • Lab automation
  • PROTAC therapeutics

Where Celeris Therapeutics is headquartered

Location

Headquarters

HQ city
Menlo Park
HQ country
United States
HQ region
North America

Markets served

Celeris Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Casino House Edge: Revenue generated from the mathematical house edge across slot machines, table games, and live dealer games. Average slot RTP stated at 95.5%, meaning the casino retains approximately 4.5% of wagers over time.
  2. VIP Program and Loyalty: Tiered VIP program with escalating perks including higher cashout limits, access to private tournaments, personal account managers, and exclusive bonus offers.
  3. Tournament Entry Fees: Formal tournaments where players compete for prize pools funded partly by entry mechanics; prizes range from $100 to $12,000.
  4. Bonus Wagering Requirements: Wagering requirements (x20-x35 multipliers) on bonus funds before withdrawal creates revenue from unfulfilled playthroughs.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goWelcome Bonus - 100 Free Spins on Great Pigsby Megaways
FreemiumPay-as-you-goFirst Deposit Match Bonus up to $1,000
Usage-basedMonthlyCashback - 10% Monthly
SubscriptionAnnualVIP Tier Benefits

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Celeris Therapeutics product offering

Product offering

Core offering

Celeris Therapeutics is a drug discovery company that uses deep learning combined with lab automation to accelerate the identification and optimization of targeted protein degradation therapeutics. Its work centers on designing degrader molecules (such as PROTACs) that can be developed into clinical assets for pharmaceutical partners or internal programs. The company operates as a discovery-stage biotech, leveraging AI-driven target identification and automated wet-lab workflows to compress traditional medicinal chemistry timelines.

Product overview

Vavada Online Casino is a single unified online gambling platform offering over 5000 games including slots, table games, live dealer games, crash games, and sports betting. The platform is accessible via desktop web browser, mobile browser, and dedicated iOS and Android applications. The ecosystem includes tournament systems, a VIP program with personalized account managers, and a bonus system with welcome bonuses, cashback, and promotional codes.

Differentiator

Problem solved

Functional benefit

Products and services

  • Targeted Protein Degradation Discovery Platform Drug discovery service that combines AI-driven target prediction with automated wet-lab experimentation to identify and optimize targeted protein degrader candidates for pharmaceutical and biotechnology partners.

Quantifiable outcome

  • Average 95.5% RTP across slots and table games, meaning 95% of bets return with multipliers from x1.1 to x100,000
  • +3 more outcomes

Companies that use Celeris Therapeutics

Customer profile

Segments4 records

Ideal customer profiles1 record

Celeris Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Celeris Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • Curaçao Gaming Control BoardcoreOthers · 1 January 2017Regulatory licensing authority providing international gaming license for legal operation. The regulator monitors random algorithm functioning, payout fund availability, and security against hacking to protect player rights.
  • 41 Gaming Providers (NetEnt, Pragmatic Play, Play'n Go, Yggdrasil, PG Soft, Red Tiger, Quickspin, iSoftBet, Hacksaw Gaming, and others)coreTechnology or IntegrationContent partnership providing over 5,000 casino game titles across slots, table games, live dealer, and crash game categories. Providers include 1x2 Gaming, Amatic, Belatra Games, BGaming, Blueprint Gaming, EGT Digital, ELK, Endorphina, Habanero, Igrosoft, NetEnt, Nolimit City, Playson, Playtech, Push Gaming, Thunderkick, Yggdrasil, and others.
  • Content Creator/Streamer PartnersminorGTM or Marketing PartnerAffiliate partners who stream casino gameplay on YouTube, provide reviews and tutorials, and distribute promotional codes to their audiences. Contact support for full partner list.
  • 20 Financial Services (Payment Processors)coreTechnology or IntegrationPayment processing partnerships enabling deposits and withdrawals across 20 currencies including cryptocurrency. Services ensure seamless financial operations without commissions.

Scale indicators8 records

Recent moves5 records

Expansion highlights4 records

Celeris Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arvinas: Pioneer and leader in clinical-stage PROTAC-based protein degradation. Most directly comparable to Celeris on the TPD modality, though at much later stage with partnered assets (Pfizer, Bayer) and FDA-submitted programs.
  • Kymera Therapeutics: Clinical-stage TPD company with multiple degrader programs and major pharma partnerships (Sanofi, Vertex). Directly competes with Celeris for talent, targets, and pharma BD opportunities in protein degradation.
  • C4 Therapeutics: Clinical-stage TPD company developing small-molecule degraders (e.g., CFT7455 for multiple myeloma). Direct peer in the protein degradation space with comparable scientific focus on targeted protein destruction.
  • Foghorn Therapeutics: Discovery-stage TPD and chromatin-targeted company. Similar early-stage profile to Celeris and competing in the same protein-degradation talent and partnership ecosystem.
  • Insilico Medicine: AI-native drug discovery company combining generative deep learning with automated wet-lab biology. Closest comparable on the AI/ML + lab automation thesis underlying Celeris's platform.
  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput automated biology with ML. Comparable technology stack and modality-agnostic approach to Celeris's AI + lab automation model.
  • Schrödinger: Computational drug discovery platform combining physics-based modeling with ML. Comparable in offering ML-driven discovery tools to pharma, though more mature, publicly traded, and software-licensing-heavy in business model.
  • Generate Biomedicines: AI-driven generative biology platform designing protein therapeutics. Overlapping AI + lab automation thesis with Celeris, though focused on biologics generation rather than small-molecule TPD.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company with substantially more capital, compute, and AlphaFold-derived IP. A broader incumbent in AI-native drug discovery and a credible long-term competitor for pharma BD deals.
  • Amgen: Large biopharma with internal TPD investment and partnerships (e.g., with Arvinas and Kymera). Represents both a structural competitive threat to TPD-discovery startups and a potential partner/acquirer for Celeris's platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Celeris Therapeutics social profiles

Digital presence

Celeris Therapeutics compliance and trust

Trust signal

Compliance1 record

Celeris Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celeris Therapeutics leadership team

Management profile

Number of profiles

Celeris Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celeris Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celeris Therapeutics

What does Celeris Therapeutics do?

Celeris Therapeutics is a drug discovery company that uses deep learning combined with lab automation to accelerate the identification and optimization of targeted protein degradation therapeutics. Its work centers on designing degrader molecules (such as PROTACs) that can be developed into clinical assets for pharmaceutical partners or internal programs. The company operates as a discovery-stage biotech, leveraging AI-driven target identification and automated wet-lab workflows to compress traditional medicinal chemistry timelines.

Is Celeris Therapeutics a public or private company?

Celeris Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Celeris Therapeutics founded?

Celeris Therapeutics was founded in 2017. It employs 1 to 10 people.

Where is Celeris Therapeutics based?

Celeris Therapeutics is headquartered in Menlo Park, United States, in the North America region.

How does Celeris Therapeutics make money?

Four revenue lines are on record. Casino House Edge is the primary driver. The others are VIP Program and Loyalty, tournament Entry Fees and bonus Wagering Requirements.

Who are Celeris Therapeutics's main competitors?

Direct peers on record are Arvinas, Kymera Therapeutics, C4 Therapeutics, Foghorn Therapeutics, Insilico Medicine, Recursion Pharmaceuticals, Schrödinger and Generate Biomedicines. Broad incumbents are Isomorphic Labs and Amgen.

Does Celeris Therapeutics have an API?

No public API is recorded for Celeris Therapeutics.

What industry is Celeris Therapeutics in?

Celeris Therapeutics's product category is Biotechnology Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TracxnTop startups in HealthTech SaaS in Austria (Oct, 2025)The article presents a curated list of top HealthTech SaaS startups in Austria, highlighting companies such as Imagebiopsy, DAPHOS, Inno Phore, and Celeris Therapeutics. It provides specific operational details for these entities, including their founding years, locations within Austria, funding stages, and total capital raised. The report also notes industry trends, such as an average annual launch rate of two new companies over the past decade.EIN PresswireCeleris Therapeutics to receive 12.5 million Euros in funding from the European Innovation CouncilCeleris Therapeutics has been selected to receive 12.5 million Euros in funding from the European Innovation Council's Accelerator program, comprising a 2.5 million Euro grant and 10 million Euros in financing. This investment brings the company's total Series A funding to 22.5 million Euros, marking Austria's largest Series A financing in the biotech sector. The funds will be utilized to advance drug development programs, expand its AI-driven platform, and grow its research center in Graz.The European Life Sciences Web PortalCeleris Therapeutics GmbH. (2/10/22). "Press Release: CelerisTx Announces $4.4m Financing to Advance Pipeline of Novel Proximity Inducing Compound". Menlo Park, CA.Celeris Therapeutics, a Menlo Park, California and Graz, Austria-based drug discovery company, closed a $4.4 million Series Seed round from Pace Ventures Enigma, i&i Biotech Fund and Apex Ventures, with R42 Group and Longevitytech.fund following. The company has raised $6 million total, including public grants from FFG and AWS, and plans to build a laboratory in Graz and fund three in-house programs in neurology and oncology.